Apple Inc. (NASDAQ:AAPL) belongs to Consumer Goods sector. Its net profit margin is 22.50% and weekly performance is -0.06%. On last trading day company shares ended up $125.61. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is -1.58%. Apple Inc. (NASDAQ:AAPL) said that, it made 73 percent of all profits in the smartphone sector, despite just having nine percent of global handset sales.
Twenty-First Century Fox, Inc. (NASDAQ:FOXA) shares fell -0.03% in last trading session and ended the day at $33.66. FOXA Gross Margin is 34.60% and its return on assets is 17.30%. Twenty-First Century Fox, Inc. (NASDAQ:FOXA) quarterly performance is -1.32%. Twenty-First Century Fox, Inc. (NASDAQ:FOXA) was downgraded by Zacks from a “hold” rating to a “strong sell” rating in a research note issued on Thursday.
On 14 July, 3M Company (NYSE:MMM) shares advanced 0.20% and was closed at $156.78. MMM EPS growth in last 5 year was 10.60%. 3M Company (NYSE:MMM) year to date (YTD) performance is -3.39%. On 29 June, 3M Company (NYSE:MMM) said that, its $2.5 billion acquisition of Capital Safety Projects last week turned more than a few heads in both the safety and office supply industry.
Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $58.19. Company weekly volatility is calculated as 1.25% and price to cash ratio as 10.54. Merck & Co. Inc. (NYSE:MRK) showed a weekly performance of 0.34%.Merck & Co. Inc. (NYSE:MRK) will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Biogen Inc. (NASDAQ:BIIB) shares advanced 2.29% in last trading session and ended the day at $400.20. BIIB Gross Margin is 88.10% and its return on assets is 23.30%. Biogen Inc. (NASDAQ:BIIB) quarterly performance is -5.52%. On 2 July, Biogen Inc. (NASDAQ:BIIB) said that, it will broaden its gene therapy pipeline by signing a partnership with Applied Genetic Technologies Corp. worth about $1 billion to develop ophthalmology treatments.